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Abstract
The aim of the work was to determine the diagnostic value of the markers of surfactant protein D (SP-D) and C-reactive 
protein (C-RP) in patients with community-acquired pneumonia (CAP) with concomitant arterial hypertension (AH) and its effects 
on the activity of the inflammatory process.
The study included 79 people. Among them, 63 patients with CAP and 16 healthy individuals who were a control group. 
Depending on the presence of hypertension, the patients were divided into two groups. The first group included 26 patients with 
CAP with AH, the second – 37 patients with CAP without AH. All patients were given general-clinical methods of examination, 
radiography of the chest organs in two projections. Plasma levels of SP-D and C-RP were determined.
Reliable connection (p<0.05) was determined between the presence of AH and the probability of occurrence of CAP (OR – 
odds ratio 2.27 [95 % CI 1.05–4.94]). The level of SP-D and C-RP in patients with AH on the first day was significantly higher than 
in healthy subjects (p<0.05). In patients in the first group, SP-D levels were significantly higher (p<0.05) for the first, third and ninth 
day relative to the second group. The existence of a direct tie of average strength between the presence of AH and SP-D (R=0.41, 
p<0.05) has been determined. The presence of a direct correlation link of mean strength (R=0.38; p<0.05) between the AH and the 
level of C-RP indicates that arterial hypertension in patients with CAP increases the activity of the systemic inflammatory response.
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1. Introduction
Community-acquired pneumonia (CAP), as a disease, remains one of the most important 
unresolved issues in modern pulmonology [1]. Cardiovascular system dysfunction is almost a con-
stant companion of the CAP and develops from the first hours, with blood circulation disturbances 
often determine the prognosis and the result of the CAP itself. The spectrum of these violations is 
varied and depends on the severity of the process [2].
The freaquency of arterial hypertension (AH) can reach 63.9 % with the damage to target 
organs in patients with CAP. Along with this, the development of anemia is accompanied by viola-
tions of microcirculation, which occurs in the mechanism of formation of hypertension, factors of 
non-specific inflammation characterized by an increase in C-reactive protein (C-RP) [3, 4]. Reduc-
ing the surfactant protein D (SP-D) may be due to the absorption and destruction of SP-D by the 
alveolar macrophages, which, due to damage to the pulmonary epithelium and infiltration of capil-
laries, causes SP-D to leak into the systemic circulation [5]. The presence of SP-D in the systemic 
circulation can contribute to the development of cardiovascular disease and mortality in patients 
with CAP, as its role in the development of endothelial dysfunction is known [6]. It is also important 
that in the vascular wall SP-D can perform the same anti-inflammatory function as in the lungs or 
vice versa, leading to a pro-inflammatory reaction [7].
Recent studies have revealed several mechanisms for violation or SP-D modifications that 
contribute to its systemic leakage from the lungs, while the circulatory level SP-D is a promising 
biomarker to determine the degree of damage to the lung tissue [8, 9]. The work performed on 
mice showed a connection between a decrease in alveolar SP-D levels and an increase in oxidative 
mechanisms [10, 11]. The SP-D concentration gradient thus allows leakage into the bloodstream 
SP-D with acute and chronic lung injury, as confirmed in experimental studies in mice [11]. Inter-
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pretation of the quantitative evaluation of SP-D in alveolar fluid and serum in various pulmonary 
diseases may be a hindrance because anti-SP-D antibodies may have different susceptibilities in 
the oxidation process [7, 8]. In recent years, it has been shown that SP-D has different antimicrobial 
and anti-inflammatory effects, affects lipid metabolism and shows pro-inflammatory effects in the 
walls of vessels, which increases the risk of atherosclerosis. The common polymorphism of SP-D 
is associated with atherosclerosis and diabetes, as well as metabolic disorders due to its effect on 
vascular endothelium [6, 12]. This review summarizes the importance of studying the circulating 
level of SP-D, the ability to interact in a diagnostic program with already well-known markers of 
systemic inflammation and the effect or dependence on the presence of comorbidity in patients 
with CAP in a hospital. 
2. Aim of research
Determination of the diagnostic value of markers SP-D and C-RP in patients with CAP with 
concomitant arterial hypertension and its effect on the activity of the inflammatory process.
3. Materials and methods
The study included 79 people who were on the treatment in the pulmonologic department of 
the Mechnikov Regional Clinical Hospital and in the therapeutic department of the City Clinical Hos-
pital No. 6 for the period from 2013 to 2016. Among them, 63 patients with CAP, who were diagnosed 
with CAP of 2 and 3 clinical groups and 16 healthy individuals, who were the control group.
In order to study the effect of comorbid hypertension on the severity of the inflammatory 
process, the patients were divided into two groups. To the first group included 26 patients with CAP 
with AH, the second -- 37 patients with CAP without AH. Duration of hypertension in the first 
group in 35 % of cases was more than 10 years, in 45 % of cases - from 5 to 10 years and in 20 % of 
cases – less than 5 years. The average systolic blood pressure level was 145±2.4 mm Hg.
Compared to the clinical course, it should be noted that in the first group, the inflammatory 
process in the lung tissue according to X-ray examination in the form of infiltration was detected 
on one side in 64 %, bilateral – 36 %, whereas in the second group, the one-side process was found 
in 84 %, and bilateral at 16 %. The course of the disease in patients with concomitant hypertension 
was characterized by a longer period of the disease.
Criteria for inclusion of patients in the study: age 18 and over; the presence of clinical and 
radiological signs of the inflammatory process in the lungs in patients with CAP; the presence of 
concomitant arterial hypertension in patients with CAP. Criteria for exclusion of patients from the 
study: refusal of the patient to participate in the study; the duration of antibiotic therapy for more 
than 24 hours; use in the therapeutic program for any nosology over the past three months of anti-
bacterial treatment; the presence of a disease for tuberculosis, malignant neoplasms, AIDS, alcohol 
or drug addiction; the presence of any other severe pulmonologic pathology.
The average age of patients in the first group was 52±2.6 years, among them 52 % of men 
and 48 % of women. The average age of patients in the second group was 45±3.1 years, among 
them 46 % men and 54 % women. In patients with the first group in 62 % of cases the body tem-
perature reached low-grade markers, 38 % – febrile ones, whereas in patients of the second group 
the distribution of subfebrile and febrile levels in the percentage ratio was 49 to 51, respectively. 
The average level of leukocytes in the first group was 14.7±4.9×109/ml, in the second – 13.8± 
±4.9109/ml. The average level of erythrocyte sedimentation rate was 32.6±3.6 mm/g and 27.4± 
±4.4 mm/g respectively in the first and second groups.
At the research stage, evaluation of the general condition and clinical symptoms in patients 
with infectious neuropathy was conducted according to a single scheme: for 1–2 days, 3–4 and 
9–10 days from the moment of admission to the department. All patients were given general-clini-
cal methods of examination, radiography of the chest organs in two projections.
The plasma level of SP-D was determined by immuno-enzymatic analysis using Hycult 
Biotech (the Netherlands) reagents according to the manufacturer’s protocol. The plasma level of 
C-RP was determined using the IT-CRP 2* 1S reagents (Lachema, Slovakia) by immunoturbi-
metric method using the Microlab-200 photometer according to the protocols of the manufacturer.
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The obtained results were analyzed using the Microsoft Office Excel program and the STA-
TISTICA 6.1 software (StatSoftInc., Serial number AGAR909E415822FA) using descriptive meth-
ods (the description of the central tendency of quantitative attributes was performed with normal 
distribution in the form of an average arithmetic and standard error M±m; in the opposite case in 
the form of median and interquat-wise Me [25–75 %], 95 % confidence interval (CI) was calculated 
to determine the range of indicators in the population, and analytical statistics methods were used 
References [13].
4. Results of the research 
In the course of the study, the results of simple logistic regression analysis revealed a reliable 
connection (p<0.05) between the presence of hypertension and the probability of the occurrence of 
CAP (OR – odds ratio 2.27 [95 % CI 1.05 – 4.94]). There was no statistically significant relationship 
between the presence of hypertension and the severity of CAP (p˃0.05).
According to the rank correlation analysis, the existence of a direct correlation between 
the level of SP-D and the presence of hypertension in patients in the first group was determined 
(R=0.41, p˂0.05).
It was also confirmed that there is a direct correlation connection of average strength 
(R=0.38; p<0.05) between the comorbid AH and the C-RP level, based on the Spirman rank cor-
relation coefficient.
In the conditions of the study, the correlation analysis of the results did not reveal a probable 
relationship between the plasma levels of C-RP and SP-D in patients in the first group (R=0.16, 
p>0.05) and the second group (R=0.24, p> 0.05).
Results of measurements of plasma level of C-reactive protein in patients of the first and 
second groups are presented in Table 1.
The level of C-RP was significantly higher in patients with both groups in healthy sub-
jects (p<0.001) and on average increased to 73.22–94.70 mg/l, while the maximum values 
reached 405 mg/l.
As a result of the analysis, it was determined that the level of C-RP in patients with CAP on 
the first day was significantly higher than that of healthy subjects (p<0.05), and subsequently to the 
third day it gradually decreased in both groups (p<0.05), compared with the previous indicators 
and reached the normal values for the ninth day and did not differ from the control group (p>0.05).
In the process of comparing the data obtained from the first and second groups, it was 
determined that the level of C-RP in patients with concomitant hypertension on the first day was 
characterized by the presence of statistical tendency to higher values (p=0.067) in patients in the 
first group by 23 %, the third day, the level C-RP decreased and was significantly higher (p<0.05) 
in patients in the first group by 44 %. There was a significant difference between the C-RP indexes 
in the patients in the first group and the control group (p<0.05) in the ninth day, while the second 
group’s statistical significance was not statistically significant in relation to the control group. The 
C-RP indexes of the first and second groups had a difference of 43 % for the ninth day.
Table 1
Change in the average levels of C-RP in the course of the inflammatory process in patients with CAP in 
comparison with the control group
Groups C-RP, the first day 
Me [25–75 %] mg/l 
C-RP, the third day 
Me [25–75 %] mg/l
C-RP, the ninth day 
Me [25–75 %] mg/l
First group  
(CAP with AH), n=26
94.70 
[58.44–171.6]°#
48.42 
[15.3–132.95]*°#
8.97 
[6.31–9.35]*° #
Second group
(CAP without AH), n=37
73.22  
[34.81–199.52]°
27.04  
[16.07–102.61]°*
5.12  
[4.1–6.25]*
Control group 4.47 [3.28–5.82]
Note: * – p <0.05 according to the Wilcoxon criterion relative to the foreground value in each group separately; ° – p <0.05 accord-
ing to the Mann-Whitney criterion relative to the control group; # – p <0.05 according to the Mann-Whitney criterion between the 
groups depending on the presence of hypertension
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Changes in SP-D levels during the course of the process obtained in patients in our study in 
the process of assessing the severity of inflammation are presented in Table 2.
The level of SP-D in patients with the first and second groups for the first day of the statisti-
cal data was significantly higher than the control group (p˂0.002). On average, the values of SP-D 
in both groups were determined within the range 429.119-608.708 ng / ml for the first day and were 
significantly higher in the first group (p˂0.05). The maximum values of SP-D in patients reached 
731.261–897.405 ng/ml and were determined mainly for bilateral lung injury.
Table 2
Change in the average levels of SP-D in the course of the inflammatory process in patients with CAP in 
comparison with the control group 
Groups SP-D, the first day 
Me [25–75 %] ng/ml
SP-D, the third day 
Me [25–75 %] ng/ml
SP-D, the ninth day 
Me [25–75 %] ng/ml
First group  
(CAP with AH), n=26
608.708 
[532.000–663.51]°ˆ
788.821  
[695.617–807.681]*°ˆ 
373.494  
[250.329–491.36]*°ˆ
Second group  
(CAP without AH), n=37
429.119 
[326.851–471.083]°ˆ
582.144 
[473.602–622.831]*°ˆ
279.362 
[194.268–354.423]*ˆ
Control group 238.050 [144.736–372.132]
Note: * – p<0.05 according to the Wilcoxon criterion relative to the foreground value in each group separately; ° – p<0.05 according 
to the Mann-Whitney criterion relative to the control group; ˆ  – p<0.05 according to the Mann-Whitney criterion between the groups 
depending on the presence of hypertension
In the period from the first to the third day, SP-D indices increased, they were significantly 
higher (p<0.05) relative to the SP-D index of the first day of both groups and the control group 
(p<0.005). From the third to the ninth day marker values gradually decreased, statistically the data 
were significantly lower than the previous values (p<0.001).
However, the data obtained in the first group were significantly higher (p<0.05) for the con-
trol group and SP-D indicators of the second group.
Based on the results obtained, the average SP-D values for the first group with concomitant 
hypertension were 608.708 ng/ml and were significantly higher (p<0.05) for the mean of patients 
in the second group – 429.119 ng/ml. For the third day, there was no statistic difference between 
the mean values of SP-D in both groups, however, there was a tendency (p=0.059) to higher values 
in patients with the first (788.821 ng/ml) and the second group (582.144 ng/ml), respectively. On 
the ninth day, the indicators gradually approached the values of the control group, but the level of 
SP-D was significantly higher (p<0.05) in patients in the first group (373.494 ng / ml) relative to the 
second group (279.362 ng/ml) and statistically different from the control group (p<0.05). There was 
no statistically significant difference between the level of SP-D in patients with the second group 
and the control group (p<0.05).
5. Discussion of the results
Specific pulmonary biomarkers that would be available and could be used for diagnosis, 
assessment of the course of the infectious process, and the effectiveness of the proposed therapeutic 
strategies are the aims of many studies [14]. To solve the problems, an analysis of the effectiveness 
of the use of markers in patients with CAP was performed, depending on the presence of hyper-
tension in terms of comparison with the control group. In the problems of modern medicine, con-
comitant hypertension in patients with CAP increases the frequency of complications 2.5 times, 
more than three times the rate of development of pleurisy, lengthens the duration of pulmonary 
infiltration [15].
For patients with CAP is characteristic an increase in C-RP and its subsequent reduction 
in the treatment [16], as well as the marker helps in diagnostic determination of the sharpening of 
the chronic process and the direct presence of the acute inflammatory process of the lungs [17]. 
However, in both cases, the C-RP level after the therapeutic program is not statistically different 
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from that of the control group, which corresponds to the data obtained in our study. The pres-
ence of concomitant hypertension increases the activity of the systemic inflammatory response. 
This is confirmed by the results of the correlation analysis, according to which, there is a direct 
average strength of the relationship between the presence of hypertension and the level of C-RP. 
Patients in the first group were characterized by significantly higher levels of C-RP (p˂0.05). 
Increased levels of C-RP in patients with cardiac pathology are associated with changes in vas-
cular stiffness, atherosclerosis and the development of damage to target organs and increased 
cardiovascular manifestations [18].
To determine the effect of hypertension on the activity of the inflammatory process and 
damage to the lung tissue, SP-D levels were studied in patients of both groups at the first, third and 
ninth day. Thus, in patients with the first group in all three observation points, the data obtained 
were higher relative to the levels of SP-D of the second group, which is related to the influence of 
hypertension as a factor that characterizes the higher severity of the systemic and local inflam-
matory response during acute processes, defining injuries pulmonary tissue [19]. The study by 
Grith L Sorensen and co-authors showed the presence of SP-D in endothelial cells and its involve-
ment in modulating the local inflammatory response [20], which in turn indicates the feedback of 
the effect of the development of the process of inflammation in the lungs caused by bacterial agents 
[21] on the possible complications of concomitant arterial hypertension.
The presence of comorbid hypertension in patients with CAP is accompanied by an increase 
in the level of SP-D in the bloodstream, which for the ninth day is characterized by significantly 
higher levels of SP-D (p<0.05) in patients with CAP. Higher SP-D rates were also determined in 
patients with multiple lesion of the lung on the one hand, indicating a marked increase in the area 
of lung tissue damage and bacterial infiltration and the relationship between pathological changes 
in the body in which the violation occurs as a consequence of primary changes in their own turn, 
reinforce each other [22].
Thus, the obtained data indicate that SP-D is capable of displaying the activity of inflam-
mation and the severity of the disease [23], to increase its circulating level in the bloodstream 
during the period of the inflammatory process of the lung and at the same time increase the risk 
of complication of the course of hypertension that in its queue in the future requires the search 
for additional possibilities for a rapid decrease in the level of circulating SP-D in the treatment of 
infectious processes of the lung.
When discussing reports of SP-D genetic associations with a significant disease list [23, 24] 
and the clinical utility of circulating SP-D for prediction of respiratory diseases [24], it should be 
noted that the current study has a further direction for its development. Prospective studies consid-
er the development of SP-D therapy [24], and the open question remains about the possibility of in-
fluencing the pathogenetic component of the inflammatory process in the treatment program [25].
6. Conclusions
1. Relative connection (p<0.05) between the presence of arterial hypertension and the prob-
ability of occurrence of community-acquired pneumonia (OR – odds ratio 2.27 [95 % CI 1.05 – 
4.94]) was determined based on the results of simple logistic regression analysis.
2. Concomitant arterial hypertension in patients with community-acquired pneumonia in-
creases the activity of the systemic inflammatory response, which is confirmed by the results of the 
correlation analysis of the C-RP (Spearman rank correlation coefficient R=0.38; p<0.05).
3. The existence of a direct link of average strength between the presence of arterial hy-
pertension and the level of surfactant protein D (R=0.41, p<0.05), which characterizes a higher 
expressiveness of the local inflammatory response during acute processes, reflecting damage to the 
pulmonary tissue.
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